boehringer ingelheim glp-1 advances triple-agonist obesity drug to clinic glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement | Boehringer Ingelheim
Pay in 4 interest-free payments of $6.32 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12




![Fragment [1-25]-Tirzepatide](https://www.daicelpharmastandards.com/wp-content/uploads/2025/04/dcti-d-571.png)
















